Neovascular Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Neovascular Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-03Clinical Trial Results: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 clinical trial results evaluating the efficacy and safety of ONS-5010 in subjects with neovascular age-related macular degeneration.
-
EMA approval · 2026-07-24New treatment option for neovascular age-related macular degeneration
EMA announces Susvimo as a new treatment option for neovascular age-related macular degeneration, delivered via an ocular implant to reduce …
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders [Phase 3]
Phase 3 trial assessing the safety of ONS-5010 in subjects with visual impairment due to retinal disorders completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-30Clinical Trial Results: A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 trial results for ONS-5010 in neovascular age-related macular degeneration completed with posted results.
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD [Phase 2, Phase 3]
Pivotal Phase 2/3 study of ABBV-RGX-314 (RGX-314) gene therapy for neovascular age-related macular degeneration evaluates subretinal deliver…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD [Phase 3]
Phase 3 trial update evaluating 36-week refill exchanges of Port Delivery System with ranibizumab in neovascular age-related macular degener…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Extension Study for the Port Delivery System With Ranibizumab (Portal) [Phase 3]
A Phase 3 extension study for the Port Delivery System with ranibizumab in neovascular age-related macular degeneration is currently recruit…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Phase I/II Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]
Phase I/II trial update evaluating PRL3-zumab for neovascular age-related macular degeneration; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD [Phase 3]
Phase 3 pivotal study update on RGX-314 gene therapy for neovascular age-related macular degeneration (nAMD), with recruitment ongoing under…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration [Phase 3]
A Phase 3 clinical trial evaluating a single intravitreal injection of 4D-150 for neovascular age-related macular degeneration is currently …
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) [Phase 3]
A Phase 3 clinical trial evaluating the injection burden, adverse events, disease activity, and long-term visual acuity preservation of Sura…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD) [Phase 2]
Phase 2 trial results for SYL1801 in patients with neovascular age-related macular degeneration have been completed, focusing on dose-findin…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
A Bayer-sponsored clinical trial project in Germany aims to quantify how many patients suffer from major eye diseases and explores new metho…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) [Phase 4]
A Phase 4 clinical trial is investigating corneal endothelial cell changes in participants with neovascular age-related macular degeneration…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B. [Phase 2, Phase 3]
This clinical trial update describes a 96-week multicenter Phase 2/3 study of OCUL101 for neovascular age-related macular degeneration, with…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
A real-world study investigating Faricimab (Vabysmo) for neovascular age-related macular degeneration and diabetic macular edema is currentl…
-
CLINICAL_TRIALS other · 2026-04-08Clinical Trial Update: A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD [Phase 3]
A Phase 3 clinical trial is evaluating the efficacy and safety of Sanhuang Jingshiming Pills for neovascular age-related macular degeneratio…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) [Phase 1]
Clinical trial update on EXG102-031 long-term follow-up in patients with neovascular age-related macular degeneration (wet AMD); Phase 1 stu…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study [Phase 3]
This is a Phase 3 trial extension evaluating the long-term safety of the intravitreal axitinib implant (OTX-TKI) in participants with neovas…
-
FDA approval · 2026-04-02FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)
FDA approved a supplemental application for EYLEA HD, a high-dose formulation of aflibercept, expanding the product's labeling.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
This is an observational study sponsored by Bayer evaluating how well aflibercept 8 mg works for visual impairment due to neovascular age-re…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Extension Study for the Port Delivery System With Ranibizumab (Portal) [Phase 3]
Extension study for the Port Delivery System delivering ranibizumab for neovascular age-related macular degeneration is currently recruiting…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD [Phase 3]
Phase 3 study evaluating 36-week refill exchanges of Port Delivery System delivering ranibizumab for neovascular age-related macular degener…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
This clinical trial update evaluates the durability of three monthly loading doses of Faricimab in treatment-naïve Neovascular age-related m…
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration [Phase 3]
Phase 3 clinical trial comparing QL1207H Injection to aflibercept for neovascular age-related macular degeneration is not yet recruiting.